drugset / Trial / NCT00753844
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer
Phase 1
Completed
7 enrolled
Kinki University
Human Genome Center, Institute of Medical Science, University of Tokyo · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
Timeline
- Start
- 2006-11
- Primary completion
- 2009-06
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | URLC10 | Peptide | 1 mg | Other |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Other |